Clinical trials: Myocardial Infarction
Type 2 Myocardial Infarction
Enhancing Cardiac Rehabilitation Attendance After Secondary Myocardial Infarction Through Clinician Messaging and Motivational Calls
The goal of this clinical trial is to determine if a behavioral intervention can increase attendance at cardiac rehabilitation (CR) after secondary/type 2 myocardial infarction in adult patients.
- Trial name
- ATTEND-CR (NCT07485491)
- Testing
- Clinician-level intervention, Patient-level intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndrome, Acute Myocardial Infarction
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- VERONICA (NCT04654052)
- Testing
- Clopidogrel, Previous treatment
- Where
- 19 sites in Spain
- Volunteers
- 637 people
- Sponsor
- Fundación EPIC
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
ST Elevation Myocardial Infarction
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST…
- Trial name
- NCT05601999
- Testing
- GNR-060, Metalyse
- Where
- 11 sites in Russia
- Volunteers
- 244 people
- Sponsor
- AO GENERIUM
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
CHIP in Health and Disease
Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic…
- Conditions
- Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndrome
- Trial name
- CHIP2 (NCT07780552)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Type 2 Diabetes
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.
- Trial name
- NCT06779929
- Testing
- Tirzepatide, Dulaglutide, Semaglutide
- Where
- United States
- Volunteers
- 70,000 people
- Sponsor
- Brigham and Women's Hospital
Acute Chest Pain, NSTEMI - Non-ST Segment Elevation MI
Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)
The PRESC1SE-MI study compares two algorithms for triage of patients presenting with chest pain and symptoms of heart attack (myocardial infarction) to the emergency department.
- Trial name
- PRESC1SE-MI (NCT05649384)
- Testing
- European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm, European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm
- Where
- 20 sites in United States, Australia and 9 more
- Volunteers
- 64,374 people
- Sponsor
- University Hospital, Basel, Switzerland
Myocardial Infarction (MI)
Impact of Pre-Hospital and Hospital Delays on Myocardial Infarction Outcomes
The goal of this prospective observational study is to investigate the impact of pre-hospital and hospital delays on the outcomes of myocardial infarction (MI) patients admitted to Al-Kadhimiya Teaching Hospital, Baghdad.
- Trial name
- PHHD-MI (NCT06738498)
- Where
- Iraq
- Volunteers
- 200 people
- Sponsor
- Al-Nahrain University
Acute Coronary Syndromes, Dyslipidemia
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein…
- Trial name
- EARLY-BIRD ACS (NCT07824323)
- Testing
- bempedoic acid, Ezetimibe, High-Intensity Statin Therapy
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Taipei Medical University Hospital
Cardiogenic Shock, Acute Myocardial Infarction
Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
This is a prospective, single-center, observational pilot study of the investigational NIRSense Tissue Oximetry Sensor System (Envello Core), a noninvasive wearable sensor patch that uses near-infrared spectroscopy (NIRS) and…
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
- Trial name
- NCT07825363
- Testing
- NIRSense Tissue Oximetry Sensor System
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NIRSense Inc.
ST Elevation (STEMI) Myocardial Infarction, Contrast Induced Nephropathy (CIN)
Beyond the Mehran Risk Score: Predictive Value of Total Ischemic Time for Contrast-Induced Nephropathy in ST Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.
Contrast-Induced Nephropathy (CIN) is a serious complication following primary percutaneous coronary intervention (PCI) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI).
- Conditions
- ST Elevation (STEMI) Myocardial Infarction, Contrast Induced Nephropathy (CIN), Acute Kidney Injury
- Trial name
- NCT07826572
- Testing
- Total Ischemic Time Evaluation
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assiut University
Neglect, Hemispatial, Stroke, Cardiovascular
Implementation of IVS3 for Upper Limb Motor Recovery
This study measures participant satisfaction and upper extremity function in outpatients with chronic stroke when exposed to the IVS3 device.
- Conditions
- Neglect, Hemispatial, Stroke, Cardiovascular, Mirror Movement, Motor Activity
- Trial name
- NCT06483230
- Testing
- Intensive Visual Stimulation Device
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
ST-segment Elevation Myocardial Infarction (STEMI)
Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.
- Trial name
- FEND-AMI (NCT06548204)
- Testing
- Fexofenadine Hydrochloride
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Coronary Syndrome
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission.
- Trial name
- ACS (NCT07102628)
- Testing
- Inclisiran
- Where
- 69 sites in Argentina, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myocardial Infarction (AMI)
Acute MI UDMI Staging Diagnosis by High-sensitivity Cardiac Troponin-I
TROP-MI-STAGE is a multicenter retrospective diagnostic study designed to evaluate the role of high-sensitivity cardiac troponin I (hs-cTnI) in the diagnosis and clinical stage classification of acute myocardial infarction as…
- Trial name
- TROP-UDMI-ID (NCT07163988)
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Rohan Dharmakumar
Cardiogenic Shock Acute, STEMI - ST Elevation Myocardial Infarction
Hong Kong Cardiogenic Shock Initiative
Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is a severe condition with high mortality. Early revascularization and Impella device (Abiomed) support improve outcomes.
- Conditions
- Cardiogenic Shock Acute, STEMI - ST Elevation Myocardial Infarction, Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction
- Trial name
- HK CSI (NCT07323238)
- Where
- Hong Kong
- Volunteers
- 320 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
"Discovery2" Study of Using MCG at Emergency Departments
The purpose of this research is to collect the magnetic signals from the heart to identify features that may help Emergency Department (ED) doctors differentiate high and low risk patients for heart related chest pain.
- Conditions
- Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain, NSTE-ACS (NSTEMI and UA)
- Trial name
- Discovery2 (NCT07822581)
- Testing
- Magnetocardiography
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- SB Technology, Inc.
Myocardial Infarction, Hypertension
Reducing Blood Pressure in Patients With High Cardiovascular Risk
BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system.
- Conditions
- Myocardial Infarction, Hypertension, Stroke
- Trial name
- BP-REACH (NCT05937685)
- Testing
- BP REACH Intervention
- Where
- 4 sites in United States
- Volunteers
- 546 people
- Sponsor
- University of Southern California
Myocardial Infarction, Thrombosis
Non-invasive Coronary Thrombus Imaging to Define These Cause of Acute Myocardial Infarction
We now have very sensitive blood tests that can pick up damage to the heart and find patients who have had a heart attack. However, whilst this is welcome, it does not identify what causes the heart attack and can sometimes pick…
- Trial name
- NCT06113510
- Testing
- Hybrid 18F-GP1 positron emission tomography and coronary computed tomography coronary angiography
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Edinburgh